Citi Pharma Ltd
Shariah compliantAlphaGen's view
Members only- Alpha scoreHow this quarter's business compares, scored 0–100
- Fair valueWhat the stock may be worth, against today's price
- Trend signalWhether the price trend is up, down or stopping
- Sector rankWhere it stands among its sector peers
Latest results
Quarter: Apr–Jun 2026In the Apr–Jun 2026 quarter, CPHL's sales rose 8% to Rs 3.3bn, from Rs 3.1bn, and profit after tax was a loss of Rs 92.7mn, against Rs 214.0mn (compared with Apr–Jun 2025).
Earnings per share were -Rs 0.41, against Rs 0.94 a year earlier.
At Rs 65.14, CPHL trades at 15.7 times earnings, with a dividend yield of 5.4%.
- P/E ratio
- 15.7
- Dividend yield
- 5.4%
- Dividend payout
- 0%
- of earnings
- Return on equity
- 7%
- Net margin
- 6.0%
- trailing twelve months
- Debt to equity
- 0.29
CPHL quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Apr–Jun 2026 | Rs 3.3bn | -Rs 92.7mn | -2.8% | -Rs 0.41 | — |
| Jan–Mar 2026 | Rs 3.1bn | Rs 275.0mn | 8.9% | Rs 1.21 | — |
| Oct–Dec 2025 | Rs 4.3bn | Rs 404.0mn | 9.3% | Rs 1.77 | — |
| Jul–Sep 2025 | Rs 3.4bn | Rs 204.0mn | 6.1% | Rs 0.89 | Rs 3.50 |
| Apr–Jun 2025 | Rs 3.1bn | Rs 214.0mn | 7.0% | Rs 0.94 | Rs 3.50 |
| Jan–Mar 2025 | Rs 3.3bn | Rs 220.0mn | 6.6% | Rs 0.96 | — |
| Oct–Dec 2024 | Rs 3.5bn | Rs 257.0mn | 7.3% | Rs 1.12 | — |
| Jul–Sep 2024 | Rs 3.2bn | Rs 201.0mn | 6.2% | Rs 0.88 | — |
CPHL annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Jun 2026 | Rs 14.1bn | Rs 790.3mn | Rs 3.46 | — |
| Year to Jun 2025 | Rs 13.2bn | Rs 892.0mn | Rs 3.90 | Rs 3.50 |
| Year to Jun 2024 | Rs 12.4bn | Rs 833.0mn | Rs 3.65 | Rs 3.25 |
| Year to Jun 2023 | Rs 12.4bn | Rs 658.0mn | Rs 2.88 | Rs 2.50 |
| Year to Jun 2022 | Rs 9.8bn | Rs 636.0mn | Rs 2.78 | — |
Balance sheet and price
Balance sheet as of Jun 2026- Total assets
- Rs 18.3bn
- Shareholders' equity
- Rs 10.8bn
- Cash & bank
- Rs 208.8mn
- Total debt
- Rs 3.1bn
- Current ratio
- 1.25
- 3-month high
- Rs 83.87
- 3-month low
- Rs 65.14
- 1-month change
- -13.4%
- 3-month change
- -20.4%
Read more about CPHL
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 927.73P/E 11.1
- AGPAGP LtdRs 157.87P/E 12.7
- BFBIOBF Biosciences LtdRs 127.51P/E 20.0
- FEROZFerozsons Laboratories LtdRs 325.07P/E 16.4
- GLAXOGlaxoSmithKline Pakistan LtdRs 316.42P/E 10.4
- HALEONHaleon Pakistan LtdRs 680.74P/E 12.7
- HINOONHighnoon Laboratories LtdRs 948.13P/E 12.1
- HPLHoehcst Pakistan LtdRs 3905.85P/E 10.4
- IBLHLIBL HealthCare LtdRs 42.52P/E 19.1
- LIVENLiven Pharma LimitedRs 31.14
- MACTERMacter International LtdRs 259.64P/E 15.3
- OTSUOtsuka Pakistan LtdRs 366.30P/E 14.4
CPHL: common questions
What is CPHL's share price?
Citi Pharma Ltd (CPHL) last closed at Rs 65.14 on the Pakistan Stock Exchange.
Does CPHL pay a dividend?
Citi Pharma Ltd reported no dividend for the year to Jun 2026.
What were CPHL's latest results?
In the Apr–Jun 2026 quarter, CPHL's sales rose 8% to Rs 3.3bn, from Rs 3.1bn, and profit after tax was a loss of Rs 92.7mn, against Rs 214.0mn (compared with Apr–Jun 2025).
What is CPHL's P/E ratio?
At Rs 65.14, CPHL trades at 15.7 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.